The Impact of Pipeline Drugs on Pharmaceutical Spending C. Daniel Mullins, Ph.D. Francis Palumbo, Ph.D., J.D. Bruce Stuart, Ph.D. University of Maryland.

Slides:



Advertisements
Similar presentations
Trend in Prescription Drug Abuse In 2004, 19.1 million Americans were current illicit drug users (7.9% of the U.S. population) 1 In 2004, 19.1 million.
Advertisements

Johan Polder, PhD | Professor in Health Eonomics
1 Exploration of Health Care Providers Behavior to Keep Their Revenues after Reduction of Payment Generosity --- A Case of Drug Payment in Taiwan Likwang.
Pharmacy Benefit Managers (PBMs)
National Health Expenditure Projections, 2012–22: Slow Growth until Coverage Expands and Economy Improves Gigi A. Cuckler, Andrea M. Sisko, Sean P. Keehan,
Controlling Drug Prices: What Canada Does Joel Lexchin MD School of Health Policy & Management York University.
R e l e a s e d: m a r c h 3 1, Cost-drivers of public drug plans in canada E l e n a l u n g u Manager, NPDUIS, PMPRB 2015 CADTH Symposium.
Montana University System URx: Rethinking our Rx program: A New Strategic Approach.
“Influence of age on the management of heart failure: Findings from Get With the Guidelines–Heart Failure (GWTG-HF)” Daniel E. Forman, MD; Christopher.
Innovations: Using a Clinical Pharmacist as a Vehicle for Successful P4P Outcomes Lisa Meland, B.S., PharmD. Helen Pervanas, R.Ph. WellPoint-WellPoint.
© Henley Business School 2008 Dr. Giampiero Favato Henley Business School University of Reading SEFAP University of Milan Long term sustainability of SSN.
Trends In Health Care Industry KNH 413. Difficult questions What is health insurance? What is health care versus health insurance? Is one or both a right.
The Facts About Rising Health Care Costs.
TAYLOR MELANSON Providing Prescription Drug Coverage to the Elderly: America’s Experiment with Medicare Part D By Mark Duggan, Patrick Healy, and Fiona.
Impact of Multi-Tiered Copayments on Cost and Use of Prescription Drugs among the Elderly Presented at AcademyHealth Annual Research Meeting Presented.
3rd Baltic Conference on Medicines Economic Evaluation, Reimbursement and Rational Use of Pharmaceuticals Pricing and Reimbursement of Pharmaceuticals.
Specialty Pharmacy: Today’s Prescription for a Better Tomorrow Steve Miller, MD Chief Medical Officer.
HRAs and HSAs: How Are They Impacting Patient Behavior? Early Cost & Use Evidence with a Focus on Pharmaceuticals & Hospital Admissions Stephen T Parente.
State Strategies: Expanding Prescription Drug Access Dee Mahan Families USA November 1, 2002.
1 Multinational Comparisons of Health Systems Data, 2009 Gerard F. Anderson, Ph.D. and Patricia Markovich Johns Hopkins University November 2009 Support.
Gaps in Drug Benefits: Impact on Utilization and Spending for Drugs Used by Medicare Beneficiaries with Serious Mental Illness Linda Simoni-Wastila, PhD.
Consumer-Driven Health Plans: Early Cost & Use Evidence with a Focus on Pharmaceuticals & Hospital Admissions Stephen T Parente Roger Feldman Jon B Christianson.
Exhibit 25.1 Annual Percentage Changes in the Prescription Drug Price Index and Prescription Drug Expenditures, Copyright 2011 Health Administration.
Prescription Drug Trends Sean Keehan, Senior Economist Office of the Actuary Centers for Medicare and Medicaid Services Middle Atlantic Actuarial Club.
Inside the Black Box: How Actuaries Price Health Insurance Academy Health Annual Research Meeting June 8 th 2004 Lisa F. Tourville, ASA, MAAA Vice President.
Focus on the Drug Payment Methods Landscape Academy of Managed Care Pharmacy April 17, 2009.
2006 Drug Trend Julayna Meyer, R.Ph, MBA Vice President Trend Management.
Helping patients breathe more easily with affordable prescriptions Presented to Pulmonary-Allergy Advisory Committee U.S. Food and Drug Administration.
Health care costs concern Americans most By JIM ABRAMS Associated Press Writer
Controlling Drug Prices: What Canada Does
Medicare Savings Due to Prescription Drug Coverage for Near-poor Elders Christine Bishop, Ph.D. 1 Andrew Ryan, M.A. 1 Daniel Gilden, M.S. 2 Cindy Parks.
Individual Insurance Benefits to be Available under Health Reform Would Have Cut Out-Of-Pocket Spending in Steven C. Hill Center for Financing,
Consumer-Driven Health Plans: Early Cost & Use Evidence with a Focus on Pharmaceuticals Stephen T Parente Jon B Christianson Roger Feldman August, 2004.
Dual Eligibles with Mental Disorders and Medicare Part D: How are They Faring? Julie Donohue University of Pittsburgh Haiden Huskamp Harvard Medical School.
Evaluating the Impact of Medicare Part D on the Virginia Preferred Drug List Program Justin Lester, PharmD, MBA First Health Services Corporation August.
Strictly confidential How to achieve sustainability in rapidly changing environment? Pavle Marjanović, Country Manager for Actavis Republic of Serbia and.
1 Medicare Reform: Implications for Pharmaceutical Manufacturers G. Lawrence Atkins, PhD Schering-Plough Corporation January 14, 2004.
The National Health Expenditure Accounts Team
The Effect of Consumer Driven Health Plans on Pharmaceutical Cost & Use: Do 3-Tier Plans Have a Competitor? Stephen T Parente Jon B Christianson Roger.
Rapid Penetration of COX2 Inhibitors in Non-Steroidal Antiinflammatory Drug Market: an Implication to Hospital Cost Containment Policy Supon Limwattananon,
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015 Average annual growth rate of prescription drug spending per capita.
IMPROVING ECONOMIC PRESCRIBING IN A TEACHING HOSPITAL THROUGH AN EDUCATIONAL STRATEGY TO PROMOTE GENERIC PRESCRIBING.
Managed Care Pharmacy Financials January 15, 2015.
The Cost of Reference-Priced Generic Drug Coverage.
Why are the Costs of Medications Increasing and What Can Be Done About It? William H. Shrank, M.D., M.S.H.S. April 15, 2016.
Source: Kaiser Family Foundation analysis of National Health Expenditure (NHE) Historical ( ) data from Centers for Medicare and Medicaid Services,
Medicaid Influence in the Drug Market Dana Costea PhD student, Department of Economics, Lehigh University Franklin Carter Assistant Professor, Marketing.
Confidential and Proprietary Information © 2012 Express Scripts, Inc. All Rights Reserved 1 AGING-RELATED MEDICATIONS: COST AND UTILIZATION PATTERNS Presenter:
Peterson-Kaiser Health System Tracker What are the recent and forecasted trends in prescription drug spending?
Mental Health and Substance Abuse Prescription Drug Spending Trends: Medicaid and Privately Insured Populations American Public Health Association Annual.
Changes to AMP & Best Price: Impact on 340B Pricing February 1, 2008 Long Beach, California 4 th Annual 340B Coalition Winter Conference University of.
Quality patients value sustainability partnership Value of generic medicines.
Infrastructure Spending: After the Great Recession and Historically
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015
Italy - Evidence package
American Public Health Association Annual Meeting November 5, 2007
Pharmaceutical Spending the United States
The Basics of Pharmacy Benefit Management (PBM)
National Trends in Per Capita Pharmaceutical Spending, 1980–2015
2018 and Beyond: Outlook and Turning Points
Health Spending per Capita, 2009 Adjusted for Differences in Cost of Living
Out-of-pocket costs for Rx drugs are expected to increase, but will likely represent a smaller portion of overall Rx spending Percent of total Rx spending.
Nat. Rev. Clin. Oncol. doi: /nrclinonc
Growth in prescription spending had slowed, but increased rapidly in 2014 and 2015
How much is health spending expected to grow?
Public opinion on prescription drugs and their prices
Diabetes econonomy2 Amini Masoud 1397.
Public opinion on prescription drugs and their prices
How much is health spending expected to grow?
Public opinion on prescription drugs and their prices
Presentation transcript:

The Impact of Pipeline Drugs on Pharmaceutical Spending C. Daniel Mullins, Ph.D. Francis Palumbo, Ph.D., J.D. Bruce Stuart, Ph.D. University of Maryland School of Pharmacy

Pharmaceutical expenditures have risen significantly in recent years Source: Levit K et. al. “Health Spending In 1998: Signals of Change” Jan/Feb 2000, Health Affairs: 19(1)

Purpose: project future drug spending –Methods: straight line actuarial projectionsstraight line actuarial projections focus on major drugs/drug classesfocus on major drugs/drug classes –Sources: Expenditure data ( ):Expenditure data ( ): –top 100 drugs (proxy for existing) –newly marketed drugs (proxy for pipeline) Price data: Average Wholesale Price (AWP)Price data: Average Wholesale Price (AWP) Utilization data: number of prescriptionsUtilization data: number of prescriptions (published in American Druggist) (published in American Druggist) University of Maryland Study

Overall, Rx expenditures will increase 15-18% annually from

Increased price and use of existing drugs account for 60 percent of future spending increases 5-6% 4-5% 1-2% Pipeline drugs include replacement therapies and new therapies for which no equivalent currently exists.

Expenditures on pipeline drugs account for 40 percent of future spending increases 5-6% 1-2% Pipeline drugs include replacement therapies and new therapies for which no equivalent currently exists.

60% 3% 37% New drugs are most likely to exhibit price increases *Top 100 Drugs 2% 70% 28% **Recently Marketed Drugs * *Most frequently prescribed dosages * All dosages

CASE STUDY: While use of pain relievers is fairly constant... NSAID Volume Source: PCS Health Systems, Data Warehouse; Eligibility File

NSAID Costs Source: PCS Health Systems, Data Warehouse; Eligibility File... per capita spending has increased by 46%

The number of prescriptions will continue to rise

CASE STUDY: New drugs are adopted rapidly and bring in new patients Source: IMS America; June 1998, November ,000 1,540,000 Lipitor

What’s in the Pipeline? Blockbuster drugsBlockbuster drugs “Me too” drugs“Me too” drugs Lifestyle drugsLifestyle drugs Top classes of pipeline drugsTop classes of pipeline drugs –Biotechnology drugs –Cardiovascular drugs –Antidepressants –Anti-cancer –Erectile dysfunction

What other factors could influence future spending? Aging population DTC advertising Lifestyle drugs New technology Increase Decrease Generic drugs Pharmacy cost management Reductions in other spending?

Factors with uncertain impact Legislative and regulatory issues Other demographic changes Internet Mergers and changes in drug distribution

Conclusions Expenditures will continue to rise at a double digit rate Pipeline drugs account for 40 percent of projected expenditure increasesPipeline drugs account for 40 percent of projected expenditure increases Existing drugs account for the remaining 60 percent of projected expenditure increasesExisting drugs account for the remaining 60 percent of projected expenditure increases Price continues to be an important factorPrice continues to be an important factor